Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of MaxCyte Inc (NASDAQ: MXCT) closed at $1.7 in the last session, up 1.80% from day before closing price of $1.67. In other words, the price has increased by $1.80 from its previous closing price. On the day, 0.47 million shares were traded. MXCT stock price reached its highest trading level at $1.725 during the session, while it also had its lowest trading level at $1.65.
Ratios:
We take a closer look at MXCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.27 and its Current Ratio is at 7.74. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 25 ’25 when Hemrajani Rekha sold 10,684 shares for $2.09 per share. The transaction valued at 22,378 led to the insider holds 39,893 shares of the business.
Swirsky Douglas J bought 50,000 shares of MXCT for $64,500 on Aug 13 ’25. The CHIEF FINANCIAL OFFICER now owns 161,811 shares after completing the transaction at $1.29 per share. On Aug 13 ’25, another insider, Masoud Maher, who serves as the President and CEO of the company, bought 75,000 shares for $1.37 each. As a result, the insider paid 102,915 and bolstered with 175,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MXCT now has a Market Capitalization of 181345824 and an Enterprise Value of 93778816. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.27 while its Price-to-Book (P/B) ratio in mrq is 1.01. Its current Enterprise Value per Revenue stands at 2.725 whereas that against EBITDA is -2.029.
Stock Price History:
The Beta on a monthly basis for MXCT is 1.19, which has changed by -0.5255682 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, MXCT has reached a high of $5.20, while it has fallen to a 52-week low of $1.26. The 50-Day Moving Average of the stock is 5.79%, while the 200-Day Moving Average is calculated to be -23.26%.
Shares Statistics:
According to the various share statistics, MXCT traded on average about 754.79K shares per day over the past 3-months and 1210150 shares per day over the past 10 days. A total of 106.64M shares are outstanding, with a floating share count of 98.26M. Insiders hold about 7.89% of the company’s shares, while institutions hold 72.10% stake in the company. Shares short for MXCT as of 1763078400 were 3014662 with a Short Ratio of 4.01, compared to 1760486400 on 3434451. Therefore, it implies a Short% of Shares Outstanding of 3014662 and a Short% of Float of 2.8399997999999997.
Earnings Estimates
A comprehensive evaluation of MaxCyte Inc (MXCT) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.05 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.33 and -$0.41 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.27, with 6.0 analysts recommending between -$0.16 and -$0.44.
Revenue Estimates
According to 6 analysts, . The current quarter’s revenue is expected to be $9.3M. It ranges from a high estimate of $10.4M to a low estimate of $8.5M. As of . The current estimate, MaxCyte Inc’s year-ago sales were $8.69MFor the next quarter, 6 analysts are estimating revenue of $8.84M. There is a high estimate of $9.38M for the next quarter, whereas the lowest estimate is $7.83M.
A total of 7 analysts have provided revenue estimates for MXCT’s current fiscal year. The highest revenue estimate was $36.1M, while the lowest revenue estimate was $34.5M, resulting in an average revenue estimate of $35.41M. In the same quarter a year ago, actual revenue was $38.63MBased on 7 analysts’ estimates, the company’s revenue will be $39.21M in the next fiscal year. The high estimate is $42.9M and the low estimate is $37.5M.
